Enterprise Value
-22.42M
Cash
51.8M
Avg Qtr Burn
-4.408M
Short % of Float
0.90%
Insider Ownership
26.18%
Institutional Own.
30.94%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Roluperidone (5-HT2A antagonist) Details Central nervous system illness, Mental health, Schizophrenia Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
Seltorexant (Orexin2 antagonist) Details Insomnia, Mood disorders | Failed Discontinued |